PulseSight Technologies recently announced the successful dosing of the first patient in the phase I clinical trial ...

The trial will evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Healthcare professionals must stop supplying the affected batch, quarantine stock, and return it to suppliers.

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X ...

Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in ...